Flushing out of cerebrospinal fluid as a therapy for acute cerebellar dysfunction caused by high dose of cytosine arabinoside: A case report

Journal of Pediatric Hematology/Oncology

Volumn 28, Issue 12, 2006, Pages 837-839

  Pellier, Isabelle ^a   Leboucher, Bertrand ^a   Rachieru, Petronela ^a   Ifrah, Norbert ^a   Rialland, Xavier ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Cerebral spinal fluid; Cytosine arabinoside; Fushing out; Leukemia; Neurologic toxicity

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; IDARUBICIN; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; ATAXIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CASE REPORT; CEREBELLUM DISEASE; CEREBROSPINAL FLUID; CONTINUOUS INFUSION; DISEASE COURSE; DISORIENTATION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DYSARTHRIA; FEMALE; HUMAN; LOW DRUG DOSE; LUMBAR PUNCTURE; MULTIPLE CYCLE TREATMENT; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; VISUAL HALLUCINATION; WHOLE BODY RADIATION;

ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; CEREBELLAR DISEASES; CEREBROSPINAL FLUID; CYTARABINE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE;

EID: 33845695717     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31802d3e2d     Document Type: Article

References (16)

1. Dworking LA, Goldman RD, Zivin LS, et al. Cerebellar toxicity following high-dose cytosine arabinoside. J Clin Oncol. 1985;3:613-616.
2. Baker WJ, Royer GL Jr, Weiss RB. Cytarabine and neurologic toxicity. J Clin Oncol. 1991;9:679-693.
3. Herzig RH, Hines JD, Herzig GP, et al. Cereballar toxicity with high-dose cytosine arabinoside. J Clin Oncol. 1987;5:927-932.
4. Shaw PJ, Procopis PG, Menser MA, et al. Bulbar and pseudobulbar palsy complicating therapy with high-dose cytosine arabinoside in children with leukemia. Med Pediatr Oncol. 1991;19:122-125.
5. Hasle H. Cerebellar toxicity during cytarabine therapy associated with renal insufficiency. Cancer Chemother Pharmacol. 1990;27:76-78.
6. Jolson HM, Bosco L, Bufton MG, et al. Clustering of adverse drug events: analysis of risk factors for cerebellar toxicity with high-dose cytarabine. J Natl Cancer Inst. 1992;84:500-505.
7. Pankaj M, Sushil M, Vivek L, et al. Cytarabine-induced neurotoxicity responding to methyl-prednisolone. Am J Hematol. 2004;77:416.
8. Salinsky MC, Levine RL, Aubuchon JP, et al. Acute cerebellar dysfunction with high-dose ARA-C therapy. Cancer. 1983;51:426-429.
9. Stentoft J. The toxicity of cytarabine. Drug Safety. 1990;5:7-27.
10. Damon LE, Plunkett W, Linker CA. Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D- arabinofuranosyluracil following the repeated intravenous administration of high and intermediate-dose 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1991;51:4141-4145.
11. Rubin EH, Andersen JW, Berg DT, et al. Risk factors for high-dose cytarabine neurotoxicity: an analysis of cancer and leukemia group B trial in patients with acute myeloid leukemia. J Clin Oncol. 1992;10:948-953.
12. Smith GA, Damon LE, Rugo HS, et al. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol. 1997;15:833-839.
13. Creutzig U, Zimmermann M, Ritter J, et al., the AML-BFM Study Group. Treatment strategies and long-term results in pediatric patients treated in four consecutive AML-BFM trials. Leukemia. 2005;19:2030-2042.
14. Smith FO, Alonzo TA, Gerbing RB, et al., the Children's Cancer Group. Long-term results of children with acute myeloid leukemia: a report of three consecutive phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia. 2005;19:2054-2062.
15. Perel Y, Auvrignon A, Leblanc T, et al. French LAME (Leucemie Aigúe Myeloblastique Enfant) Cooperative Group. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit - multicenter studies of the French LAME (Leucemie Aigúe Myeloblastique Enfant) Cooperative Group. Leukemia. 2005;19:2082-2089.
16. Boesen P, Fallingborg J, Spaun E. Severe persistent cerebellar dysfunction complicating cytosine arabinoside therapy. Acta Med Scand. 1988;224:189-191.